FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection By Ogkologos - January 14, 2026 123 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for safety and efficacy is based on the findings from the PALOMA-3 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Volunteering with Pride: Brett’s award-winning involvement with Cancer Research UK June 15, 2023 Man Gets His First Haircut In 15 Years To Join The... August 21, 2019 Philanthropist Simon Collins: “I realised I could make a difference by... September 6, 2021 How Anxiety Impacts People With Cancer and How to Cope February 10, 2022 Load more HOT NEWS Pembrolizumab Continues to Demonstrate Durable Efficacy with No New Safety Signals... Adding Atezolizumab to Chemotherapy Does Not Improve Outcomes in Patients Who... Trial Results Highlight Changing Lung Cancer Treatment Landscape Study Shows that Disrupted Gut Bacteria May Contribute to the Spread...
